ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2013
Pediatric diffuse intrinsic pontine glioma patients from a single center.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nimotuzumab as Additional Therapy for GLIOMA in Pediatric and Adolescent: A Systematic Review.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Efficacy of chemoradiotherapy in pediatric H3K27M-mutant diffuse intrinsic pontine glioma: a study based on single-center and SEER data.Journal of neuro-oncology · 2026Article
- Radiological complete response in diffuse intrinsic pontine glioma: a case report.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma.CNS neuroscience & therapeutics · 2023Article
- Pediatric brain tumor cell lines exhibit miRNA-depleted, Y RNA-enriched extracellular vesicles.Journal of neuro-oncology · 2022Article
- Targeted therapy for pediatric diffuse intrinsic pontine glioma: a single-center experience.Therapeutic advances in medical oncology · 2022Article
- Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2019Article
- Detecting the H3F3A mutant allele found in high-grade pediatric glioma by real-time PCR.Journal of neuro-oncology · 2016Article
- DIPG in Children - What Can We Learn from the Past?Frontiers in oncology · 2015Review
- Diffuse intrinsic pontine glioma in children and adolescents: a single-center experience.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2014Article
- Management of diffuse pontine gliomas in children: recent developments.Paediatric drugs · 2013Review
- Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic Review.Advances in radiation oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognosis of children with diffuse intrinsic pontine gliomas (DIPG) is dismal. This study aims to evaluate the characteristics and treatment outcome of children with DIPG in a single center.
methodsWe reviewed the outcome of children with DIPG treated at the Oncology Institute of Istanbul University from February 1999 to May 2012.
resultsFifty children (26 female, 24 male) with the median age of 7 years were analyzed. The median duration of symptoms was 30 days. All patients received radiotherapy (RT). Before the year 2000, 12 patients received only RT. Thirty-eight had concomitant and/or adjuvant chemotherapy with RT. Between 2000 and 2004, 17 patients received cis-platinum or vincristine as sensitizers during RT and CCNU + vincristine combination after RT. Since 2004, 21 patients received temozolomide (TMZ) concomitantly during RT and as adjuvant chemotherapy after RT. The median survival time of all patients was 13 months (1-160 months). Patients receiving RT + TMZ had a significantly higher overall survival than patients with only RT (p = 0.018). Patients receiving RT + chemotherapy other than TMZ also had a significantly higher overall survival than patients receiving only RT (p = 0.013). Patients receiving RT + TMZ + and chemotherapy other than TMZ had a significantly higher survival than patients receiving only RT (p = 0.005).
conclusionIn our series, patients receiving RT + TMZ and also patients receiving RT + chemotherapy other than TMZ had a significantly higher overall survival than patients treated with only RT. Hence, administering chemotherapy during and after RT seems to prolong survival in some DIPG patients.
Indexed as
Identifiers
23224361What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.